Cargando…

663. Characteristics, Treatment Patterns, and Outcomes of Outpatients With Rickettsial Diseases in a Large, Commercially Insured Population: United States, 2005–2016

BACKGROUND: Rickettsial diseases (RD) include Spotted Fever Group (SFG) Rickettsiosis, Ehrlichiosis, Anaplasmosis, Typhus Group (TG) and Rickettsialpox, among others. Doxycycline is the treatment of choice in all age groups; early treatment based on clinical diagnosis is important to prevent severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Binder, Alison, Peterson, Amy E, Armstrong, Paige
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253626/
http://dx.doi.org/10.1093/ofid/ofy210.670
_version_ 1783373539681763328
author Binder, Alison
Peterson, Amy E
Armstrong, Paige
author_facet Binder, Alison
Peterson, Amy E
Armstrong, Paige
author_sort Binder, Alison
collection PubMed
description BACKGROUND: Rickettsial diseases (RD) include Spotted Fever Group (SFG) Rickettsiosis, Ehrlichiosis, Anaplasmosis, Typhus Group (TG) and Rickettsialpox, among others. Doxycycline is the treatment of choice in all age groups; early treatment based on clinical diagnosis is important to prevent severe and fatal outcomes. SFG, Ehrlichiosis, and Anaplasmosis are nationally notifiable in the United States, but data on treatment patterns are not collected. METHODS: We conducted a retrospective analysis using Truven Health MarketScan(®) Commercial Claims and Encounters databases. We included any individual with an outpatient claim using an ICD-9/10-CM code for RD, who had one-year continuous pre- and 3 months post-diagnosis enrollment and pharmaceutical claim data. The first outpatient record with RD was considered the incident diagnosis, and those with an RD hospitalization in the prior 1 year were excluded. Epidemiologic characteristics, treatment patterns, and outcomes were summarized. RESULTS: 13,353 individuals were included; median age was 45 years (IQR: 28–55 years), 2,045 (15%) were under 18 years of age, and 51% were male. The most common diagnosis was SFG (7,133; 50%), followed by Ehrlichiosis (3,920; 30%), and Typhus (1,281; 10%); 36 individuals had >1 diagnosis. Over half (7,075; 53%) received doxycycline within 30 of the index date; of these, 3,634 (51%) received it within 14 days. The majority (5,369; 86%) were treated for at least 10 days at the recommended dose. The proportion with a pharmaceutical claim for doxycycline varied considerably across diagnoses and ranged from 24% for TG to 60% for SFG Rickettsiosis. Among the 6,278 (47%) without a claim for doxycycline, 2,185 (35%) were prescribed another antibiotic; 4,093 (28%) were not prescribed any antibiotic. Hospitalization within 30 days of the incident diagnosis was infrequent (149, 1.1%), and the majority were due to either SFR (40%) or ehrlichiosis (37%). No in-hospital deaths were recorded. CONCLUSION: RD continues to be an important cause of disease in the outpatient population, but providers are still only prescribing the recommended treatment to about half of those in whom they suspect the disease. Continued education and increased awareness is critical to prevent severe outcomes from RD. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253626
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62536262018-11-28 663. Characteristics, Treatment Patterns, and Outcomes of Outpatients With Rickettsial Diseases in a Large, Commercially Insured Population: United States, 2005–2016 Binder, Alison Peterson, Amy E Armstrong, Paige Open Forum Infect Dis Abstracts BACKGROUND: Rickettsial diseases (RD) include Spotted Fever Group (SFG) Rickettsiosis, Ehrlichiosis, Anaplasmosis, Typhus Group (TG) and Rickettsialpox, among others. Doxycycline is the treatment of choice in all age groups; early treatment based on clinical diagnosis is important to prevent severe and fatal outcomes. SFG, Ehrlichiosis, and Anaplasmosis are nationally notifiable in the United States, but data on treatment patterns are not collected. METHODS: We conducted a retrospective analysis using Truven Health MarketScan(®) Commercial Claims and Encounters databases. We included any individual with an outpatient claim using an ICD-9/10-CM code for RD, who had one-year continuous pre- and 3 months post-diagnosis enrollment and pharmaceutical claim data. The first outpatient record with RD was considered the incident diagnosis, and those with an RD hospitalization in the prior 1 year were excluded. Epidemiologic characteristics, treatment patterns, and outcomes were summarized. RESULTS: 13,353 individuals were included; median age was 45 years (IQR: 28–55 years), 2,045 (15%) were under 18 years of age, and 51% were male. The most common diagnosis was SFG (7,133; 50%), followed by Ehrlichiosis (3,920; 30%), and Typhus (1,281; 10%); 36 individuals had >1 diagnosis. Over half (7,075; 53%) received doxycycline within 30 of the index date; of these, 3,634 (51%) received it within 14 days. The majority (5,369; 86%) were treated for at least 10 days at the recommended dose. The proportion with a pharmaceutical claim for doxycycline varied considerably across diagnoses and ranged from 24% for TG to 60% for SFG Rickettsiosis. Among the 6,278 (47%) without a claim for doxycycline, 2,185 (35%) were prescribed another antibiotic; 4,093 (28%) were not prescribed any antibiotic. Hospitalization within 30 days of the incident diagnosis was infrequent (149, 1.1%), and the majority were due to either SFR (40%) or ehrlichiosis (37%). No in-hospital deaths were recorded. CONCLUSION: RD continues to be an important cause of disease in the outpatient population, but providers are still only prescribing the recommended treatment to about half of those in whom they suspect the disease. Continued education and increased awareness is critical to prevent severe outcomes from RD. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253626/ http://dx.doi.org/10.1093/ofid/ofy210.670 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Binder, Alison
Peterson, Amy E
Armstrong, Paige
663. Characteristics, Treatment Patterns, and Outcomes of Outpatients With Rickettsial Diseases in a Large, Commercially Insured Population: United States, 2005–2016
title 663. Characteristics, Treatment Patterns, and Outcomes of Outpatients With Rickettsial Diseases in a Large, Commercially Insured Population: United States, 2005–2016
title_full 663. Characteristics, Treatment Patterns, and Outcomes of Outpatients With Rickettsial Diseases in a Large, Commercially Insured Population: United States, 2005–2016
title_fullStr 663. Characteristics, Treatment Patterns, and Outcomes of Outpatients With Rickettsial Diseases in a Large, Commercially Insured Population: United States, 2005–2016
title_full_unstemmed 663. Characteristics, Treatment Patterns, and Outcomes of Outpatients With Rickettsial Diseases in a Large, Commercially Insured Population: United States, 2005–2016
title_short 663. Characteristics, Treatment Patterns, and Outcomes of Outpatients With Rickettsial Diseases in a Large, Commercially Insured Population: United States, 2005–2016
title_sort 663. characteristics, treatment patterns, and outcomes of outpatients with rickettsial diseases in a large, commercially insured population: united states, 2005–2016
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253626/
http://dx.doi.org/10.1093/ofid/ofy210.670
work_keys_str_mv AT binderalison 663characteristicstreatmentpatternsandoutcomesofoutpatientswithrickettsialdiseasesinalargecommerciallyinsuredpopulationunitedstates20052016
AT petersonamye 663characteristicstreatmentpatternsandoutcomesofoutpatientswithrickettsialdiseasesinalargecommerciallyinsuredpopulationunitedstates20052016
AT armstrongpaige 663characteristicstreatmentpatternsandoutcomesofoutpatientswithrickettsialdiseasesinalargecommerciallyinsuredpopulationunitedstates20052016